Lynne Dawkins1, Olivia Corcoran. 1. Drugs and Addictive Behaviours Research Group, School of Psychology, University of East London, Water Lane, Stratford, London, E15 4LZ, UK, l.e.dawkins@uel.ac.uk.
Abstract
RATIONALE: Electronic cigarettes are becoming increasingly popular among smokers worldwide. Commonly reported reasons for use include the following: to quit smoking, to avoid relapse, to reduce urge to smoke, or as a perceived lower-risk alternative to smoking. Few studies, however, have explored whether electronic cigarettes (e-cigarettes) deliver measurable levels of nicotine to the blood. OBJECTIVE: This study aims to explore in experienced users the effect of using an 18-mg/ml nicotine first-generation e-cigarette on blood nicotine, tobacco withdrawal symptoms, and urge to smoke. METHODS: Fourteen regular e-cigarette users (three females), who are abstinent from smoking and e-cigarette use for 12 h, each completed a 2.5 h testing session. Blood was sampled, and questionnaires were completed (tobacco-related withdrawal symptoms, urge to smoke, positive and negative subjective effects) at four stages: baseline, 10 puffs, 60 min of ad lib use and a 60-min rest period. RESULTS: Complete sets of blood were obtained from seven participants. Plasma nicotine concentration rose significantly from a mean of 0.74 ng/ml at baseline to 6.77 ng/ml 10 min after 10 puffs, reaching a mean maximum of 13.91 ng/ml by the end of the ad lib puffing period. Tobacco-related withdrawal symptoms and urge to smoke were significantly reduced; direct positive effects were strongly endorsed, and there was very low reporting of adverse effects. CONCLUSIONS: These findings demonstrate reliable blood nicotine delivery after the acute use of this brand/model of e-cigarette in a sample of regular users. Future studies might usefully quantify nicotine delivery in relation to inhalation technique and the relationship with successful smoking cessation/harm reduction.
RATIONALE: Electronic cigarettes are becoming increasingly popular among smokers worldwide. Commonly reported reasons for use include the following: to quit smoking, to avoid relapse, to reduce urge to smoke, or as a perceived lower-risk alternative to smoking. Few studies, however, have explored whether electronic cigarettes (e-cigarettes) deliver measurable levels of nicotine to the blood. OBJECTIVE: This study aims to explore in experienced users the effect of using an 18-mg/ml nicotine first-generation e-cigarette on blood nicotine, tobacco withdrawal symptoms, and urge to smoke. METHODS: Fourteen regular e-cigarette users (three females), who are abstinent from smoking and e-cigarette use for 12 h, each completed a 2.5 h testing session. Blood was sampled, and questionnaires were completed (tobacco-related withdrawal symptoms, urge to smoke, positive and negative subjective effects) at four stages: baseline, 10 puffs, 60 min of ad lib use and a 60-min rest period. RESULTS: Complete sets of blood were obtained from seven participants. Plasma nicotine concentration rose significantly from a mean of 0.74 ng/ml at baseline to 6.77 ng/ml 10 min after 10 puffs, reaching a mean maximum of 13.91 ng/ml by the end of the ad lib puffing period. Tobacco-related withdrawal symptoms and urge to smoke were significantly reduced; direct positive effects were strongly endorsed, and there was very low reporting of adverse effects. CONCLUSIONS: These findings demonstrate reliable blood nicotine delivery after the acute use of this brand/model of e-cigarette in a sample of regular users. Future studies might usefully quantify nicotine delivery in relation to inhalation technique and the relationship with successful smoking cessation/harm reduction.
Authors: Jan Czogala; Maciej L Goniewicz; Bartlomiej Fidelus; Wioleta Zielinska-Danch; Mark J Travers; Andrzej Sobczak Journal: Nicotine Tob Res Date: 2013-12-11 Impact factor: 4.244
Authors: Jonathan Foulds; Susan Veldheer; Jessica Yingst; Shari Hrabovsky; Stephen J Wilson; Travis T Nichols; Thomas Eissenberg Journal: Nicotine Tob Res Date: 2014-10-19 Impact factor: 4.244
Authors: Dale S Mantey; Melissa B Harrell; Kathleen Case; Brittani Crook; Steven H Kelder; Cheryl L Perry Journal: Drug Alcohol Depend Date: 2017-01-25 Impact factor: 4.492
Authors: Michael J Zvolensky; Lorra Garey; Nubia A Mayorga; Andrew H Rogers; Michael F Orr; Joseph W Ditre; Natalia Peraza Journal: J Behav Med Date: 2018-11-28